Xenical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients
TORGERSON, Jarl S, HAUPTMAN, Jonathan, BOLDRIN, Mark N, SJÖSTRÖM, Lars
Published in Diabetes care (2004)
Published in Diabetes care (2004)
Get full text
Journal Article
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, Jarl S., Hauptman, Jonathan, Boldrin, Mark N., Sjöström, Lars
Published in Diabetes care (01.01.2004)
Published in Diabetes care (01.01.2004)
Get full text
Journal Article
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes
Rosenstock, Julio, Balas, Bogdan, Charbonnel, Bernard, Bolli, Geremia B., Boldrin, Mark, Ratner, Robert, Balena, Raffaella
Published in Diabetes care (01.03.2013)
Published in Diabetes care (01.03.2013)
Get full text
Journal Article
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
Nauck, Michael A., Ratner, Robert E., Kapitza, Christoph, Berria, Rachele, Boldrin, Mark, Balena, Raffaella
Published in Diabetes care (01.07.2009)
Published in Diabetes care (01.07.2009)
Get full text
Journal Article
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
ROSENSTOCK, Julio, BALAS, Bogdan, CHARBONNEL, Bernard, BOLLI, Geremia B, BOLDRIN, Mark, RATNER, Robert, BALENA, Raffaella
Published in Diabetes care (01.03.2013)
Published in Diabetes care (01.03.2013)
Get full text
Journal Article
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
Heymsfield, S B, Segal, K R, Hauptman, J, Lucas, C P, Boldrin, M N, Rissanen, A, Wilding, J P, Sjöström, L
Published in Archives of internal medicine (1960) (08.05.2000)
Published in Archives of internal medicine (1960) (08.05.2000)
Get more information
Journal Article
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients
Zhi, Jianguo, Zhai, Suoping, Georgy, Angela, Liang, Zhenming, Boldrin, Mark
Published in Journal of clinical pharmacology (01.05.2016)
Published in Journal of clinical pharmacology (01.05.2016)
Get more information
Journal Article
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus
Georgy, Angela, Zhai, Suoping, Liang, Zhenming, Boldrin, Mark, Zhi, Jianguo
Published in Journal of clinical pharmacology (01.06.2016)
Published in Journal of clinical pharmacology (01.06.2016)
Get more information
Journal Article
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
Nauck, Michael A, Ratner, Robert E, Kapitza, Christoph, Berria, Rachele, Boldrin, Mark, Balena, Raffaella
Published in Diabetes care (01.07.2009)
Published in Diabetes care (01.07.2009)
Get full text
Journal Article
Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
Raz, Itamar, Fonseca, Vivian, Kipnes, Mark, Durrwell, Laurence, Hoekstra, John, Boldrin, Mark, Balena, Raffaella
Published in Diabetes care (01.03.2012)
Published in Diabetes care (01.03.2012)
Get full text
Journal Article
Dose‐Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short‐Term Multiple Doses in Patients With Type 2 Diabetes Mellitus
Zhi, Jianguo, Zhai, Suoping, Boldrin, Mark
Published in Clinical pharmacology in drug development (01.05.2017)
Published in Clinical pharmacology in drug development (01.05.2017)
Get full text
Journal Article
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
Sjöström, Lars, Rissanen, Aila, Andersen, Teis, Boldrin, Mark, Golay, Alain, Koppeschaar, Hans PF, Krempf, Michel
Published in The Lancet (British edition) (18.07.1998)
Published in The Lancet (British edition) (18.07.1998)
Get full text
Journal Article
Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial
Anderson, James W, Schwartz, Susan M, Hauptman, Jonathan, Boldrin, Mark, Rossi, Maureen, Bansal, Vidhu, Hale, Cecilia A
Published in The Annals of pharmacotherapy (01.10.2006)
Published in The Annals of pharmacotherapy (01.10.2006)
Get more information
Journal Article
Comparative Evaluation of Fecal Fat Excretion Induced by Orlistat and Chitosan
Guerciolini, Roberto, Radu‐Radulescu, Lucian, Boldrin, Mark, Dallas, Jayson, Moore, Rema
Published in Obesity (Silver Spring, Md.) (01.06.2001)
Published in Obesity (Silver Spring, Md.) (01.06.2001)
Get full text
Journal Article